Connect Sign In
The FDA’s newly proposed rules would regulate all in vitro diagnostic products as medical devices if enacted. ARUP believes additional FDA oversight would disrupt the diagnostic testing market.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
ARUP Consult, a free source of expert guidance in laboratory testing, has released updated resources on testing for osteoporosis, paraneoplastic pemphigus, and epilepsy.
Forbes magazine has listed ARUP as one of the 2023 Best Employers by State based on employer recommendations from employees and others in Utah in a recent survey conducted by Statista.
Ragan Communications has recognized an ARUP program that helps staff improve their health through exercises that treat and prevent injuries that can result from the repetitive nature of work in a lab.
ARUP is gearing up for the launch of a new hematopathology webinar to be hosted by Madhu Menon, MD, PhD, FCAP. Other ARUP experts will join Menon to discuss timely issues in hematopathology testing.
A novel event organized by ARUP’s Patent Committee aimed to highlight creative solutions that may not lead to patents but still advance laboratory medicine and improve patient care.
ARUP Consult, a free source of expert guidance in laboratory testing, has released updated resources on testing for Lyme disease, diagnosing pneumonia, and evaluating infertility.
ARUP researchers and medical directors will join industry leaders at AACC 2023 to share their expertise on laboratory stewardship, workforce needs, automation, and more.
ARUP Consult, a free source of expert guidance in laboratory testing, has updated resources on testing for human papillomavirus, chronic lymphocytic leukemia, and amenorrhea.
The FDA now recommends the same assessment questions for all donors, regardless of gender or sexual orientation. ARUP Blood Services is one of the first donor centers to update processes in response.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
